Latest Impact Factor: Latest Impact Factor: : 6.506 The Official Journal of: American Thyroid Association®…
Read More
Given the evolving landscape of therapeutic options for RAIR-DTC, it is essential to highlight the importance of timely evaluating patients with advanced thyroid cancer.
Patients who have been affected by the TEPEZZA supply disruption can talk with their doctor…
Thyroid, the leading journal addressing research in thyroidology, is accepting applications for a new Editor-in-Chief.
Explore advances for thyroid cancer, hypothyroidism, Graves’ disease, immunotherapy, and more on Feb. 19-20, 2021 during ATA’s virtual meeting.
AbbVie is pleased to introduce the SYNTHROID DELIVERS PROGRAM, a direct-to-patient pharmacy program that offers…
Thyrogen Co-Pay Assistance Program is available to support patient access to Thyrogen. This program helps…
Eisai is pleased to announce that LENVIMATM (lenvatinib)is now approved for the treatment of locally…
Revised label will facilitate use of Thyrogen to greater number of patients for postoperative thyroid…
Woodcliff Lake, NJ, February 2, 2014 – Eisai Inc. announced today that the Phase 3…
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.